Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05440643 · ClinicalTrials.gov registry record · Phase 1

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

A Phase 1 study of Peanut Allergy, sponsored by ALK-Abelló A/S.

Active
Registry status
Phase 1
Development phase
192
Enrollment target
20
Study locations

NCT05440643 is a Phase 1 study of Peanut Allergy that is active but no longer recruiting, run by ALK-Abelló A/S. The registered enrollment target is 192 participants, roughly in line with the 199-participant average among 13 other Peanut Allergy trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05440643, a Phase 1 study of Peanut Allergy, is active but no longer recruiting, sponsored by ALK-Abelló A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
192 participants
Enrollment target
20
Study locations

Study Summary

This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.

Conditions Studied

Peanut Allergy

Interventions

  • OTHER Placebo
  • BIOLOGICAL Peanut SLIT-tablet

Study Locations (20)

California

  • Children's Hospital of Los Angeles - USC School of Medicine - Los Angeles
  • UCLA - Pediatrics - Los Angeles
  • Stanford University - Lucile Packard Children's Hospital - Palo Alto
  • Peninsula Research Associates (PRA) - Rolling Hills Estates
  • Eastern Virginia Medical School - Children's Hospital - San Diego
  • Allergy & Asthma Clinical Research - Walnut Creek

Florida

  • Quality Research of South Florida - Hialeah
  • MOORE-PH Dermatology - Clinical Research - Tampa
  • USF Asthma Allergy and Immunology Clinical Research Unit - Tampa

Illinois

  • Ann Robert H. Lurie Childrens Hospital of Chicago - Chicago
  • Rush University - Chicago
  • Sneeze, Wheeze, & Itch Associates, LLC - Normal

Maryland

  • Johns Hopkins University School of Medicine - Baltimore
  • Asthma, Allergy and Sinus Center - White Marsh

Arkansas

  • Arkansas Children's Hospital - Little Rock

Colorado

  • Children's Hospital Colorado - Aurora

Georgia

  • Center for Advance Pediatrics - Atlanta

Kentucky

  • Family Allergy Asthma Research Institute - Louisville

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2022-09-07
Est. Completion 2026-04
Phase Phase 1

Sponsor

ALK-Abelló A/S

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05440643

The ClinicalTrials.gov registry entry for NCT05440643 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 199-participant average among 13 other Peanut Allergy trials with a reported enrollment target. The listed sponsor is ALK-Abelló A/S, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05440643 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05440643 about?

NCT05440643 is a clinical study titled "Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy". This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.

What is the current status of trial NCT05440643?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-09-07. Estimated completion is 2026-04.

What conditions does trial NCT05440643 study?

This clinical trial studies the following conditions: Peanut Allergy.

What interventions are being tested in trial NCT05440643?

The interventions under investigation include: Placebo (OTHER), Peanut SLIT-tablet (BIOLOGICAL).

Who is sponsoring clinical trial NCT05440643?

This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05440643 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peanut Allergy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Peanut Allergy

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.